TY - JOUR
T1 - Doxorubicin retention and chemoresistance in human mesothelioma cell lines
AU - Isobe, Hiroshi
AU - Wellham, Larry
AU - Sauerteig, Antonieta
AU - Sridhar, Kasi S.
AU - Ramachandran, Cheppail
AU - Krishan, Awtar
PY - 1994/5/15
Y1 - 1994/5/15
N2 - Eight cell lines were established from the pleural effusion of 4 patients with malignant mesothelioma. The most sensitive (FCCMES-4) and the most resistant (FCCMES-2) mesothelioma cell lines had IC50 of 0.66 and 1.85 μM for doxorubicin in clonogenic assays, respectively. In comparison with murine leukemic P388 cells, mesothelioma cell lines were 7.5- to 21-fold more resistant to doxorubicin. Co-incubation with verapamil significantly increased doxorubicin retention in one of the cell lines (FCCMES-2) expressing P-glycoprotein in 16.8% of the cells. These results indicate that doxorubicin resistance may be intrinsic in refractory mesothelioma patients and P-glycoprotein-mediated drug efflux may be involved in resistance of some of the mesotheliomas.
AB - Eight cell lines were established from the pleural effusion of 4 patients with malignant mesothelioma. The most sensitive (FCCMES-4) and the most resistant (FCCMES-2) mesothelioma cell lines had IC50 of 0.66 and 1.85 μM for doxorubicin in clonogenic assays, respectively. In comparison with murine leukemic P388 cells, mesothelioma cell lines were 7.5- to 21-fold more resistant to doxorubicin. Co-incubation with verapamil significantly increased doxorubicin retention in one of the cell lines (FCCMES-2) expressing P-glycoprotein in 16.8% of the cells. These results indicate that doxorubicin resistance may be intrinsic in refractory mesothelioma patients and P-glycoprotein-mediated drug efflux may be involved in resistance of some of the mesotheliomas.
UR - http://www.scopus.com/inward/record.url?scp=0028285703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028285703&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910570423
DO - 10.1002/ijc.2910570423
M3 - Article
C2 - 7910154
AN - SCOPUS:0028285703
VL - 57
SP - 581
EP - 585
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 4
ER -